# Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

> **NCT01416571** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 78 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted

## Key facts

- **NCT ID:** NCT01416571
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-12
- **Primary completion:** 2011-11-29
- **Final completion:** 2012-09-28
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2018-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01416571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01416571, "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01416571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*